JESSICA DAVIS: Open Payments
NPI 1174063309 · GADSDEN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$565 in 28 payments from 10 companies in 2025. Trend: 2023 $302 · 2024 $180 · 2025 $565
Food & beverage: $565
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $205 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $111 |
| Mindray DS USA, Inc. | 1 | $66 |
| Alkermes, Inc. | 3 | $57 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, PATIENT MONITOR, ARISTADA, COBENFY, REXULTI, Qelbree, FANAPT.
Industry payments across AL — which companies pay providers there.
